Veterinärmedizinische Universität Wien Forschungsinformationssystem VetDoc

Grafischer Link zur Startseite der Vetmeduni Vienna

Sexl Veronika,

** = Publikationen gelistet in SCI/SSCI/Pubmed

2019

Zeitschriftenaufsatz

** Garrido-Mesa, N; Schroeder, JH; Stolarczyk, E; Gallagher, AL; Lo, JW; Bailey, C; Campbell, L; Sexl, V; MacDonald, TT; Howard, JK; Grencis, RK; Powell, N; Lord, GM (2019): T-bet controls intestinal mucosa immune responses via repression of type 2 innate lymphoid cell function. Mucosal Immunol. 2019; 12(1):51-63
Open Access Logo

** Gawish, R; Bulat, T; Biaggio, M; Lassnig, C; Bago-Horvath, Z; Macho-Maschler, S; Poelzl, A; Simonović, N; Prchal-Murphy, M; Rom, R; Amenitsch, L; Ferrarese, L; Kornhoff, J; Lederer, T; Svinka, J [and 9 others] (2019): Myeloid Cells Restrict MCMV and Drive Stress-Induced Extramedullary Hematopoiesis through STAT1. Cell Rep. 2019; 26(9):2394-2406.e5
Open Access Logo

** Kollmann, S; Grundschober, E; Maurer, B; Warsch, W; Grausenburger, R; Edlinger, L; Huuhtanen, J; Lagger, S; Hennighausen, L; Valent, P; Decker, T; Strobl, B; Mueller, M; Mustjoki, S; Hoelbl-Kovacic, A; Sexl, V (2019): Twins with different personalities: STAT5B-but not STAT5A-has a key role in BCR/ABL-induced leukemia. Leukemia. 2019;
Open Access Logo [Article in Press]

** Simonović, N; Witalisz-Siepracka, A; Meissl, K; Lassnig, C; Reichart, U; Kolbe, T; Farlik, M; Bock, C; Sexl, V; Müller, M; Strobl, B (2019): NK Cells Require Cell-Extrinsic and -Intrinsic TYK2 for Full Functionality in Tumor Surveillance and Antibacterial Immunity. J Immunol. 2019; 202(6):1724-1734

** Uras, IZ; Maurer, B; Nivarthi, H; Jodl, P; Kollmann, K; Prchal-Murphy, M; Milosevic Feenstra, JD; Zojer, M; Lagger, S; Grausenburger, R; Grabner, B; Holly, R; Kavirayani, A; Bock, C; Gisslinger, H [and 3 others] (2019): Cdk6 coordinates Jak2V617F mutant MPN via NFκB and apoptotic networks. Blood. 2019;
[Article in Press]

Publizierter (zitierfähiger) Beitrag für wissenschaftliche Veranstaltung in Proceedings (A2)

Menzl, I; Zhang, T; Grausenburger, R; Bauer, K; Grebien, F; Valent, P; Zuber, J; Gray, N; Sexl, V (2019): CDK8 degradation – preparing the ground for mTOR inhibition in ALL. -AEK Congress 2019; Feb 27 - MAR 1, 2019; Heidelberg, Germany.

2018

Zeitschriftenaufsatz

** Baumgartner, C; Toifl, S; Farlik, M; Halbritter, F; Scheicher, R; Fischer, I; Sexl, V; Bock, C; Baccarini, M (2018): An ERK-Dependent Feedback Mechanism Prevents Hematopoietic Stem Cell Exhaustion. Cell Stem Cell. 2018; 22(6):879-892.e6
Open Access Logo

** Bellutti, F; Tigan, AS; Nebenfuehr, S; Dolezal, M; Zojer, M; Grausenburger, R; Hartenberger, S; Kollmann, S; Doma, E; Prchal-Murphy, M; Uras, IZ; Höllein, A; Neuberg, DS; Ebert, BL; Ringler, A [and 12 others] (2018): CDK6 Antagonizes p53-Induced Responses during Tumorigenesis. Cancer Discov. 2018; 8(7):884-897

** Blatt, K; Menzl, I; Eisenwort, G; Cerny-Reiterer, S; Herrmann, H; Herndlhofer, S; Stefanzl, G; Sadovnik, I; Berger, D; Keller, A; Hauswirth, A; Hoermann, G; Willmann, M; Rülicke, T; Sill, H [and 6 others] (2018): Phenotyping and Target Expression Profiling of CD34 Neoplasia. 2018; 20(6):632-642
Open Access Logo

** Glasner, A; Levi, A; Enk, J; Isaacson, B; Viukov, S; Orlanski, S; Scope, A; Neuman, T; Enk, CD; Hanna, JH; Sexl, V; Jonjic, S; Seliger, B; Zitvogel, L; Mandelboim, O (2018): NKp46 Receptor-Mediated Interferon-γ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis. Immunity. 2018; 48(1):107-119.e4

** Jelenčić, V; Šestan, M; Kavazović, I; Lenartić, M; Marinović, S; Holmes, TD; Prchal-Murphy, M; Lisnić, B; Sexl, V; Bryceson, YT; Wensveen, FM; Polić, B (2018): NK cell receptor NKG2D sets activation threshold for the NCR1 receptor early in NK cell development. Nat Immunol. 2018; 19(10):1083-1092

** Nebenfuehr, S; Bellutti, F; Sexl, V (2018): Cdk6: At the interface of Rb and p53. Mol Cell Oncol. 2018; 5(5):e1511206

** Pham, HTT; Maurer, B; Prchal-Murphy, M; Grausenburger, R; Grundschober, E; Javaheri, T; Nivarthi, H; Boersma, A; Kolbe, T; Elabd, M; Halbritter, F; Pencik, J; Kazemi, Z; Grebien, F; Hengstschläger, M [and 9 others] (2018): STAT5BN642H is a driver mutation for T cell neoplasia. J Clin Invest. 2018; 128(1):387-401
Open Access Logo

** Porpaczy, E; Tripolt, S; Hoelbl-Kovacic, A; Gisslinger, B; Bago-Horvath, Z; Casanova-Hevia, E; Clappier, E; Decker, T; Fajmann, S; Fux, DA; Greiner, G; Gueltekin, S; Heller, G; Herkner, H; Hoermann, G [and 22 others] (2018): Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. Blood. 2018; 132(7):694-706

** Szappanos, D; Tschismarov, R; Perlot, T; Westermayer, S; Fischer, K; Platanitis, E; Kallinger, F; Novatchkova, M; Lassnig, C; Müller, M; Sexl, V; Bennett, KL; Foong-Sobis, M; Penninger, JM; Decker, T (2018): The RNA helicase DDX3X is an essential mediator of innate antimicrobial immunity. PLoS Pathog. 2018; 14(11):e1007397
Open Access Logo

** Uras, IZ; Maurer, B; Nebenfuehr, S; Zojer, M; Valent, P; Sexl, V (2018): Therapeutic Vulnerabilities in FLT3 -Mutant AML Unmasked by Palbociclib. Int J Mol Sci. 2018; 19(12): 3987.
Open Access Logo

** Vizzardelli, C; Gindl, M; Roos, S; Möbs, C; Nagl, B; Zimmann, F; Sexl, V; Kenner, L; Neunkirchner, A; Zlabinger, GJ; Pickl, WF; Pfützner, W; Bohle, B (2018): Blocking antibodies induced by allergen-specific immunotherapy ameliorate allergic airway disease in a human/mouse chimeric model. Allergy. 2018; 73(4):851-861

** Witalisz-Siepracka, A; Gotthardt, D; Prchal-Murphy, M; Didara, Z; Menzl, I; Prinz, D; Edlinger, L; Putz, EM; Sexl, V (2018): NK Cell-Specific CDK8 Deletion Enhances Antitumor Responses. Cancer Immunol Res. 2018; 6(4):458-466

** Witalisz-Siepracka, A; Klein, K; Prinz, D; Leidenfrost, N; Schabbauer, G; Dohnal, A; Sexl, V (2018): Loss of JAK1 Drives Innate Immune Deficiency. Front Immunol. 2018; 9:3108
Open Access Logo

** Xiao, Q; Wu, J; Wang, WJ; Chen, S; Zheng, Y; Yu, X; Meeth, K; Sahraei, M; Bothwell, ALM; Chen, L; Bosenberg, M; Chen, J; Sexl, V; Sun, L; Li, L [and 2 others] (2018): DKK2 imparts tumor immunity evasion through β-catenin-independent suppression of cytotoxic immune-cell activation. Nat Med. 2018; 24(3):262-270
Open Access Logo

Kongressbeitrag in einer Zeitschrift

** Mah, AY; Keppel, MP; Saucier, N; Sexl, V; French, AR; Cooper, MA (2018): Cox10-deficient NK cells have increased apoptosis during MCMV infection, leading to susceptibility. Immunology Meeting, Austin, TX, United States (USA), MAY 04-08, 2018. J Immunol (200), S1 168.5.

** Porpaczy, E; Tripolt, S; Holbl-Kovacic, A; Gisslinger, B; Bago-Horvath, Z; Casanova-Hevia, E; Clappier, E; Decker, T; Fajmann, S; Fux, DA; Greiner, G; Gultekin, S; Heller, G; Herkner, H; Hormann, G [and 22 others] (2018): JAK1/2 inhibitor therapy-associated lymphomas in myelofibrosis arising from a preexisting B-cell clone. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Vienna, Austria, SEP 28 - OCT 2, 2018. Oncol Res Treat (41), S4 38-39.

** Schmoellerl, J; Barbosa, I; Van der Veen, C; Eder, T; Schmidt, L; Brandstoetter, T; Maurer, B; Terlecki, S; Hormann, G; Valent, P; Jude, J; Sexl, V; Zuber, J; Grebien, F (2018): NUP98-rearranged acute myeloid leukemia expresses high levels of CDK6 and is hypersensitive to Palbociclib treatment. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Vienna, Austria, SEP 28 - OCT 2, 2018. Oncol Res Treat (41), S4 40-40.

Publizierter (zitierfähiger) Beitrag für wissenschaftliche Veranstaltung in Proceedings (A2)

Bellutti, F; Tigan, AS; Nebenfuehr, S; Dolezal, M; Zojer, M; Grausenburger, R; Höllein, A; Neuberg, DS; Villunger, A; Kollmann, K; Sexl, V (2018): CDK6 Antagonizes p53-Induced Responses during Tumorigenesis. -FASEB Conference: Transcription, Chromatin and Epigenetis; SEP 16-21, 2018; Florence, Italy.

Menzl, I; Zhang, T; Grausenburger, R; Bauer, K; Grebien, F; Kubicek, S; Valent, P; Zuber, J; Gray, N; Sexl, V (2018): CDK8 degradation - Preparing the ground for mTOR inhibition in BCR/ABL+ ALL. -23rd Congress of the European Hematogloy Association; JUNI 14-17, 2018; Stockholm, Sweden. Open Access Logo

2017

Zeitschriftenaufsatz

** Edlinger, L; Berger-Becvar, A; Menzl, I; Hoermann, G; Greiner, G; Grundschober, E; Bago-Horvath, Z; Al-Zoughbi, W; Hoefler, G; Brostjan, C; Gille, L; Moriggl, R; Spittler, A; Sexl, V; Hoelbl-Kovacic, A (2017): Expansion of BCR/ABL1(+) cells requires PAK2 but not PAK1. Br J Haematol. 2017; 179(2):229-241
Open Access Logo

** Freund, P; Kerenyi, MA; Hager, M; Wagner, T; Wingelhofer, B; Pham, HTT; Elabd, M; Han, X; Valent, P; Gouilleux, F; Sexl, V; Krämer, OH; Groner, B; Moriggl, R (2017): O-GlcNAcylation of STAT5 controls tyrosine phosphorylation and oncogenic transcription in STAT5-dependent malignancies. Leukemia. 2017; 31(10):2132-2142
Open Access Logo

** Glasner, A; Isaacson, B; Viukov, S; Neuman, T; Friedman, N; Mandelboim, M; Sexl, V; Hanna, JH; Mandelboim, O (2017): Increased NK cell immunity in a transgenic mouse model of NKp46 overexpression. Sci Rep. 2017; 7(1):13090
Open Access Logo

** Gotthardt, D; Sexl, V (2017): STATs in NK-Cells: The Good, the Bad, and the Ugly. Front Immunol. 2017; 7:694
Open Access Logo

** Greiner, G; Witzeneder, N; Berger, A; Schmetterer, K; Eisenwort, G; Schiefer, AI; Roos, S; Popow-Kraupp, T; Müllauer, L; Zuber, J; Sexl, V; Kenner, L; Sperr, WR; Valent, P; Mayerhofer, M; Hoermann, G (2017): CCL2 is a KIT D816V-dependent modulator of the bone marrow microenvironment in systemic mastocytosis. Blood. 2017; 129(3):371-382

** Krzywinska, E; Kantari-Mimoun, C; Kerdiles, Y; Sobecki, M; Isagawa, T; Gotthardt, D; Castells, M; Haubold, J; Millien, C; Viel, T; Tavitian, B; Takeda, N; Fandrey, J; Vivier, E; Sexl, V; Stockmann, C (2017): Loss of HIF-1α in natural killer cells inhibits tumour growth by stimulating non-productive angiogenesis. Nat Commun. 2017; 8(1):1597
Open Access Logo

** Lenartić, M; Jelenčić, V; Zafirova, B; Ožanič, M; Marečić, V; Jurković, S; Sexl, V; Šantić, M; Wensveen, FM; Polić, B (2017): NKG2D Promotes B1a Cell Development and Protection against Bacterial Infection. J Immunol. 2017; 198(4):1531-1542

** Linke, M; Pham, HT; Katholnig, K; Schnöller, T; Miller, A; Demel, F; Schütz, B; Rosner, M; Kovacic, B; Sukhbaatar, N; Niederreiter, B; Blüml, S; Kuess, P; Sexl, V; Müller, M [and 7 others] (2017): Chronic signaling via the metabolic checkpoint kinase mTORC1 induces macrophage granuloma formation and marks sarcoidosis progression. Nat Immunol. 2017; 18(3):293-302
Open Access Logo

** Maurer, B; Farlik, M; Sexl, V (2017): It is a differentiation game: STAT5 in a new role. Cell Death Differ. 2017; 24(6):953-954
Open Access Logo

** Sochalska, M; Schuler, F; Weiss, JG; Prchal-Murphy, M; Sexl, V; Villunger, A (2017): MYC selects against reduced BCL2A1/A1 protein expression during B cell lymphomagenesis. Oncogene. 2017; 36(15):2066-2073
Open Access Logo

** Streicher, C; Heyny, A; Andrukhova, O; Haigl, B; Slavic, S; Schüler, C; Kollmann, K; Kantner, I; Sexl, V; Kleiter, M; Hofbauer, LC; Kostenuik, PJ; Erben, RG (2017): Estrogen Regulates Bone Turnover by Targeting RANKL Expression in Bone Lining Cells. Sci Rep. 2017; 7(1):6460
Open Access Logo

** Theurich, S; Tsaousidou, E; Hanssen, R; Lempradl, AM; Mauer, J; Timper, K; Schilbach, K; Folz-Donahue, K; Heilinger, C; Sexl, V; Pospisilik, JA; Wunderlich, FT; Brüning, JC (2017): IL-6/Stat3-Dependent Induction of a Distinct, Obesity-Associated NK Cell Subpopulation Deteriorates Energy and Glucose Homeostasis. Cell Metab. 2017; 26(1):171-184.e6

** Uras, IZ; Bellutti, F; Sexl, V (2017): p27 in FLT3-driven acute myeloid leukemia: many roads lead to ruin. Haematologica. 2017; 102(8):1299-1301
Open Access Logo

** Uras, IZ; Scheicher, RM; Kollmann, K; Glösmann, M; Prchal-Murphy, M; Tigan, AS; Fux, DA; Altamura, S; Neves, J; Muckenthaler, MU; Bennett, KL; Kubicek, S; Hinds, PW; von Lindern, M; Sexl, V (2017): Cdk6 contributes to cytoskeletal stability in erythroid cells. Haematologica. 2017; 102(6):995-1005
Open Access Logo

Kongressbeitrag in einer Zeitschrift

** Borst, K; Blank, P; Flindt, S; König, M; Tegtrneyer, PK; Chhatbar, C; Skerra, J; Waibler, Z; Sexl, V; Frenz, T; Kalinke, U (2017): The role of NK cell-derived interferon-gamma in anti-viral immune responses. 5th Annual Meeting of the International-Cytokine-and-Interferon-Society (ICIS), Int Cytokine & Interferon Soc, Kanazawa, JAPAN, Japan, OCT 29-NOV 02, 2017. Cytokine (100) 59-60.

** Doma, E; Hölbl, A; Sexl, V (2017): Generation Of Immortal Murine Hematopoietic Stem/ Progenitor Cell Lines From Transgenic Mice. 22nd Congress of the European-Hematology-Association, Madrid, SPAIN, Spain, JUN 22-25, 2017. Haematologica (102), S2 304-304. Open Access Logo

** Hoelbl-Kovacic, A; Berger, A; Edlinger, L; Menzl, I; Hoermann, G; Grundschober, E; Bago-Horvath, Z; Sexl, V (2017): Maintenance Of Leukaemogenic Potential Of Bcr/Abl Plus Cells Requires Pak2 But Not Pak1 . 22nd Congress of the European-Hematology-Association, Madrid, SPAIN, Spain, JUN 22-25, 2017. Haematologica (102), S2 430-430. Open Access Logo

** Sexl, V (2017): CDK6: At the interface of Rb and p53. 2nd AACR Conference on Hematologic Malignancies - Translating Discoveries to Novel Therapies, Boston, MA, United States (USA), MAY 06-09, 2017. Clin Cancer Res (23), 24 23-23.

** Sexl, V (2017): Targeting STAT5 In Leukemogenesis - What's New. 37th SEF National Meeting with guest society: the British Pharmacology Society, Barcelona, Spain, JUN 18–21, 2017. Basic Clin Pharmacol (121), S2 32-32.

** Tripolt, S; Schneckenleithner, C; Hoelbl-Kovacic, A; Heller, G; Sexl, V (2017): Lack of Stat1 Predisposes to a Diffuse Large B-Cell Lymphoma-Like Disease. 22nd Congress of the European-Hematology-Association, Madrid, SPAIN, Spain, JUN 22-25, 2017. Haematologica (102), S2 562-562. Open Access Logo

** Uras, I; Valent, P; Sexl, V (2017): Targeted Combination Therapy With Cdk4/6 Inhibitor Palbociclib In AML. 22nd Congress of the European-Hematology-Association, Madrid, SPAIN, Spain, JUN 22-25, 2017. Haematologica (102), S2 207-208. Open Access Logo

** Vargas-Hernandez, A; Prchal-Murphy, M; Mace, EM; Carisey, AF; Orange, JS; Sexl, V; Forbes, LR (2017): Human STAT5B Mutations Cause Dysregulated Human Natural Killer Cell Maturation and Impaired Lytic Function. Meeting of the Latin-American-Society-for-Immunodeficiencies (LASID), Sao Paulo, Brazil, OCT 04-07, 2017. J Clin Immunol (37), S1 S2-S3.

Greiner, G; Witzeneder, N; Berger, A; Schmetterer, K; Eisenworth, G; Schiefer, A; Roos, S; Popow-kraupp, T; Müllauer, L; Zuber, J; Sexl, V; Kenner, L; Sperr, WR; Mayerhofer, M; Valent, P; Hoermann, G (2017): ccl-2 Is A Kit D816v-dependent Modulator Of The Bone Marrow Microenvironment In Systemic Mastocytosis: Cod: T210. Euromedlab 2017 Athen, Athen, Greece, June 11-15, 2017. Clinical Chemistry and Laboratory Medicine (55) 709-709.

Publizierter (zitierfähiger) Beitrag für wissenschaftliche Veranstaltung in Proceedings (A2)

Bellutti, F; Kollmann, K; Dolezal, M; Villunger, A; Malumbres, M; Sexl, V (2017): CDK6-p53: A non-canonical function of CDK6 in hematological malignancies. -Cell death, inflammation and cancer; JAN 10-14, 2017 ; Obergurgl, Austria.

Berger, A; Edlinger, L; Menzl, I; Hoermann, G; Grundschober, E; Bago-Horvath, Z; Sexl, V; Hoelbl-Kovacic, A (2017): Maintenance of leukaemogenic potential of BCR/ABL+ cells requires PAK2 but not PAK1. -EHA European Haematology Association ; JUN 22-25, 2017; Madrid, Spain.

Doma, E; Hoelbl-Kovacic, A; Sexl, V (2017): Generation of immortal murine hematopoietic stem/progenitor cell lines from transgenic mice. -22nd Congress of EHA (EHA22); JUN 22-25, 2017; Madrid, Spain.

2016

Zeitschriftenaufsatz

** Bauer, E; Schlederer, M; Scheicher, R; Horvath, J; Aigner, P; Schiefer, AI; Kain, R; Regele, H; Hoermann, G; Steiner, G; Kenner, L; Sexl, V; Villunger, A; Moriggl, R; Stoiber, D (2016): Cooperation of ETV6/RUNX1 and BCL2 enhances immunoglobulin production and accelerates glomerulonephritis in transgenic mice. Oncotarget. 2016; 7(11):12191-12205
Open Access Logo

** Bothur, E; Raifer, H; Haftmann, C; Stittrich, AB; Brüstle, A; Brenner, D; Bollig, N; Bieringer, M; Kang, CH; Reinhard, K; Camara, B; Huber, M; Visekruna, A; Steinhoff, U; Repenning, A [and 7 others] (2016): Antigen receptor-mediated depletion of FOXP3 in induced regulatory T-lymphocytes via PTPN2 and FOXO1. Nat Commun. 2016; 6:8576
Open Access Logo

** Bottos, A; Gotthardt, D; Gill, JW; Gattelli, A; Frei, A; Tzankov, A; Sexl, V; Wodnar-Filipowicz, A; Hynes, NE (2016): Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models. Nat Commun. 2016; 7:12258
Open Access Logo

** Gotthardt, D; Putz, EM; Grundschober, E; Prchal-Murphy, M; Straka, E; Kudweis, P; Heller, G; Bago-Horvath, Z; Witalisz-Siepracka, A; Cumaraswamy, AA; Gunning, PT; Strobl, B; Müller, M; Moriggl, R; Stockmann, C; Sexl, V (2016): STAT5 Is a Key Regulator in NK Cells and Acts as a Molecular Switch from Tumor Surveillance to Tumor Promotion. Cancer Discov. 2016; 6(4):414-429

** Kazemi, Z; Bergmayr, C; Prchal-Murphy, M; Javaheri, T; Themanns, M; Pham, HT; Strohmaier, W; Sexl, V; Freissmuth, M; Zebedin-Brandl, E (2016): Repurposing Treprostinil for Enhancing Hematopoietic Progenitor Cell Transplantation. Mol Pharmacol. 2016; 89(6):630-644
Open Access Logo

** Klose, R; Krzywinska, E; Castells, M; Gotthardt, D; Putz, EM; Kantari-Mimoun, C; Chikdene, N; Meinecke, AK; Schrödter, K; Helfrich, I; Fandrey, J; Sexl, V; Stockmann, C (2016): Targeting VEGF-A in myeloid cells enhances natural killer cell responses to chemotherapy and ameliorates cachexia. Nat Commun. 2016; 7:12528
Open Access Logo

** Majoros, A; Platanitis, E; Szappanos, D; Cheon, H; Vogl, C; Shukla, P; Stark, GR; Sexl, V; Schreiber, R; Schindler, C; Müller, M; Decker, T (2016): Response to interferons and antibacterial innate immunity in the absence of tyrosine-phosphorylated STAT1. EMBO Rep. 2016; 17(3):367-382
Open Access Logo

** Park, HJ; Li, J; Hannah, R; Biddie, S; Leal-Cervantes, AI; Kirschner, K; Flores Santa Cruz, D; Sexl, V; Göttgens, B; Green, AR (2016): Cytokine-induced megakaryocytic differentiation is regulated by genome-wide loss of a uSTAT transcriptional program. EMBO J. 2016; 35(6):580-594
Open Access Logo

** Putz, EM; Majoros, A; Gotthardt, D; Prchal-Murphy, M; Zebedin-Brandl, EM; Fux, DA; Schlattl, A; Schreiber, RD; Carotta, S; Müller, M; Gerner, C; Decker, T; Sexl, V (2016): Novel non-canonical role of STAT1 in Natural Killer cell cytotoxicity. Oncoimmunology. 2016; 5(9):e1186314
Open Access Logo

** Sadovnik, I; Hoelbl-Kovacic, A; Herrmann, H; Eisenwort, G; Cerny-Reiterer, S; Warsch, W; Hoermann, G; Greiner, G; Blatt, K; Peter, B; Stefanzl, G; Berger, D; Bilban, M; Herndlhofer, S; Sill, H [and 6 others] (2016): Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML. Clin Cancer Res. 2016; 22(8):2051-2061
Open Access Logo

** Tigan, AS; Bellutti, F; Kollmann, K; Tebb, G; Sexl, V (2016): CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation. Oncogene. 2016; 35(24):3083-3091

** Uras, IZ; Walter, GJ; Scheicher, R; Bellutti, F; Prchal-Murphy, M; Tigan, AS; Valent, P; Heidel, FH; Kubicek, S; Scholl, C; Fröhling, S; Sexl, V (2016): Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6. Blood. 2016; 127(23):2890-2902
Open Access Logo

Kongressbeitrag in einer Zeitschrift

** Maurer, B; Nivarthi, H; Prchal-Murphy, M; Wingelhofer, B; Chen, D; Winkler, S; Schlederer, M; Pham, HTT; Kenner, L; Sexl, V; Kolbe, T; Kralovics, R; Muller, M; Rülicke, T; Moriggl, R (2016): Activated Stat5 Drives Peripheral T Cell Lymphomas. 21st Congress of the European-Hematology-Association, Copenhagen, DENMARK, JUN 09-12, 2016. Haematologica (101), S1 567-567.

** Wingelhofer, B; Heyes, EC; Maurer, B; Lewis, AM; Cumaraswamy, AA; Sadovnik, I; Berger-Becvar, A; Sexl, V; Valent, P; Kubicek, S; Gunning, PT; Moriggl, R (2016): Identification of a novel STAT5 inhibitor to interfere with the oncogenic activities of STAT5 in AML. 21st Congress of the European-Hematology-Association, Copenhagen, DENMARK, JUN 09-12, 2016. Haematologica (101), S1 211-211.

Publizierter (zitierfähiger) Beitrag für wissenschaftliche Veranstaltung in Proceedings (A2)

Bellutti, F; Uras, I; Prchal-Murphy, M; Tigan, A; Rodríguez-Díez, E; Quereda, V; Malumbres, M; Sexl, V (2016): Uncoupling CDK4/6 from INK4 inhibitors – Molecular consequences for leukemogenesis. -Cellular signalling and cancer therapy; MAI 27–31, 2016 ; Cavtat, CROATIA.

Bellutti, F; Uras, ZI; Prchal-Murphy, M; Tigan, AS; Rodríguez-Díez, E; Quereda, V; Malumbres, M; Sexl, V (2016): Uncoupling CDK4/6 from INK4 inhibitors – Molecular consequences for leukemogenesis. Hematological Malignancies: from Mechanisms to Therapy; MAR 9-12, 2016; Milano, ITALY. 2016.

Blatt, K; Cerny-Reiterer, S; Hölbl, A; Sadovnik, I; Herrmann, H; Herndlhofer, S; Eisenwort, G; Hauswirth, A; Hörmann, G, Willmann, M; Rülicke, T; Sill, H; Sperr, WR; Mannhalter, C; Melo, JV; Jäger, U [and 2 others] (2016): Characterization and target expression profiles of CD34+/CD38− and CD34+/CD38+ stem- and progenitor cells in acute lymphoblastic leukemia (ALL). 8346-8346.-LBG Meeting for Health Sciences; NOV 28-29, 2016; Vienna, AUSTRIA.

Doma, E; Scheicher R, Fajmann, S; Sexl, V (2016): Generation of immortal murine hematopoietic/progenitor cell lines from trangenic mice by ectopic expression of Lhx2. -Hematopoietic Stem Cells: From the Embryo to the Aging Organism; JUNE 3-5, 2016; Heidelberg, GERMANY.

Edlinger, L; Berger-Bečvař, A; Hoelbl-Kovacic, A; Greiner, G; Hoermann, G; Sexl, V (2016): A PAK-STAT5 axis is key for tumor formation of BCR/ABL+ cells in vivo. -26th VetPharm Symposium; OCT 6-7, 2016; Munich, GERMANY.

Edlinger, L; Berger-Bečvař, A; Hoelbl-Kovacic, A; Greiner, G; Hoermann, G; Sexl, V (2016): A PAK2-STAT5 axis is key for tumor formation of BCR-ABL+ cells in vivo. -OeGHO- & AHOP-Fruehjahrstagung 2016; MAR 17-19, 2016; Vienna, AUSTRIA.

Gültekin-Tigan, AS; Grausenburger, R; Bellutti, F; Scheicher, R; Prchal-Murphy, M; Schaefer, M; Barbosa, I; Muhar, M; Bock, C; Busslinger, M; Zuber, J; Sexl, V (2016): The cyclin-dependent kinase CDK6 as key regulator of the cancer epigenome. -2nd Danube Conference on Epigenetics ; OCT 5-8, 2016; Budapest, Hungary.

Meissl, K; Witalisz-Siepracka, A; Prchal-Murphy, M; Sexl, V; Müller, M; Strobl, B (2016): Cell-extrinsic STAT1 isoform-specific functions regulate NK cell maturation. -16th Annual Meeting of the Society for Natural Immunity - NK2016; OCT 3-5, 2016; Taormina, ITALY.

Sadovnik, I; Herrmann, H; Hoelbl, A; Cerny-Reiterer, S; Warsch, W; Blatt, K; Peter, B; Hörmann, G; Eisenwort, G; Bilban, M; Sill, H; Sperr, WR; Streubel, B; Willmann, M; Rülicke, M [and 4 others] (2016): Identification of CD25 (IL-2RA) and CD26 (DPPIV) as novel markers and targets in CD34+/CD38− LSC in Ph+ CML. 8460-8460.-LBG Meeting for Health Sciences 2016; NOV 28-29, 2016; Vienna, AUSTRIA.

Scheicher R, Prchal-Murphy M, Sexl V (2016): CDK6 in hematopoietic and leukemic stem cells – cell cycle versus transcriptional Regulation. -Hematopoietic Stem Cells: From Embryo to the Aging Organism; JUN 2-5, 2016; Heidelberg, Germany.

Sexl, V (2016): NK cells - silent killers on the move. -Translational Immunology - From Target to Therapy; OCT 28-30; Würzburg, GERMANY.

Sexl, V (2016): STATs in Nk cell mediatied tumorsurveillance. -Keystone Symposia; JAN 10-15, 2016; Colorado, USA.

Sexl, V (2016): Targeting CDK6 - novel and surprising opportunities in hematology. -Dotan Hematological conference; SEP 11-14, 2016; Tel Aviv, ISRAEL.

Sexl, V (2016): JAK-STAT for the better or worse in NK cell biology. -16th Annual Meeting of the Society for Natural Immunity; OCT 2-5, 2016; Taormina, ITALY.

Sexl, V; Gotthart, D; Putz, EM; Witalisz, A; Decker, T; Strobl, B; Müller, M (2016): AK-STAT in NK cells: For the better or worse in tumour surveillance. -Cytokine JAK-STAT Signaling in Immunity and Disease; JAN 10-14, 2016; Colorado, USA.

Witalisz-Siepracka, A; Bozovic, N; Meissl, K; Lassnig, C; Sexl, V; Müller, M; Strobl, B (2016): TYK2 regulates NK cell function by cell-intrinsic and -extrinsic mechanisms. -NK 2016 - 16th Meeting of the Society for Natural Immunity; OCT 3-5, 2016; Taormina, ITALY.

Originalbeitrag in Sammelwerk

Fux, DA; Sexl, V (2016): Desinfektionsmittel. IN: Löscher, W; Richter, A [Hrsg.]: Lehrbuch der Pharmakologie und Toxikologie für die Veterinärmedizin. 4. Ed. Stuttgart, Enke Verlag, pp. 513-524. ISBN: 978-3-13-219581-3.

2015

Zeitschriftenaufsatz

** Bothur, E; Raifer, H; Haftmann, C; Stittrich, A-B; Brustle, A; Brenner, D; Bollig, N; Bieringer, M; Kang, C-H; Reinhard, K; Camara, B; Huber, M; Visekruna, A; Steinhoff, U; Repenning, A [and 7 others] (2015): Antigen receptor-mediated depletion of FOXP3 in induced regulatory T-lymphocytes via PTPN2 and FOXO1. Nature Communications 2015; 6: 8576
Open Access Logo

** Nivarthi, H; Prchal-Murphy, M; Swoboda, A; Hager, M; Schlederer, M; Kenner, L; Tuckermann, J; Sexl, V; Moriggl, R; Ermakova, O (2015): Stat5 gene dosage in T cells modulates CD8+ T-cell homeostasis and attenuates contact hypersensitivity response in mice. Allergy. 2015; 70(1):67-79

** Pathria, P; Gotthardt, D; Prchal-Murphy, M; Putz, EM; Holcmann, M; Schlederer, M; Grabner, B; Crncec, I; Svinka, J; Musteanu, M; Hoffmann, T; Filipits, M; Berger, W; Poli, V; Kenner, L [and 8 others] (2015): Myeloid STAT3 promotes formation of colitis-associated colorectal cancer in mice. Oncoimmunology. 2015; 4(4):e998529
Open Access Logo

** Prchal-Murphy, M; Witalisz-Siepracka, A; Bednarik, KT; Putz, EM; Gotthardt, D; Meissl, K; Sexl, V; Müller, M; Strobl, B (2015): In vivo tumor surveillance by NK cells requires TYK2 but not TYK2 kinase activity. Oncoimmunology. 2015; 4(11):e1047579
Open Access Logo

** Scheicher, R; Hoelbl-Kovacic, A; Bellutti, F; Tigan, AS; Prchal-Murphy, M; Heller, G; Schneckenleithner, C; Salazar-Roa, M; Zöchbauer-Müller, S; Zuber, J; Malumbres, M; Kollmann, K; Sexl, V (2015): CDK6 as a key regulator of hematopoietic and leukemic stem cell activation. Blood. 2015; 125(1):90-101

** Schiefer, AI; Kornauth, C; Simonitsch-Klupp, I; Skrabs, C; Masel, EK; Streubel, B; Vanura, K; Walter, K; Migschitz, B; Stoiber, D; Sexl, V; Raderer, M; Chott, A; da Silva, MG; Cabecadas, J [and 3 others] (2015): Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas: A Retrospective Cohort Study. Medicine (Baltimore). 2015; 94(52):e2388
Open Access Logo

** Sullivan, RP; Leong, JW; Schneider, SE; Ireland, AR; Berrien-Elliott, MM; Singh, A; Schappe, T; Jewell, BA; Sexl, V; Fehniger, TA (2015): MicroRNA-15/16 Antagonizes Myb To Control NK Cell Maturation. J Immunol. 2015; 195(6):2806-2817
Open Access Logo

Kongressbeitrag in einer Zeitschrift

** Maurer, B; Nivarthi, H; Prchal-Murphy, M; Wingelhofer, B; Chen, D; Winkler, S; Prochazkova, J; Schlederer, M; Pham, H; Loizou, JI; Kenner, L; Sexl, V; Kolbe, T; Kralovics, R; Müller, M [and 2 others] (2015): An activating STAT5 mutation is sufficient for Peripheral T Cell Lymphoma formation. 3rd Annual Meeting of the International-Cytokine-and-Interferon-Society (ICIS), Bamberg, GERMANY, OCT 11-14, 2015. Cytokine (76), 1 77-77.

** Witalisz-Siepracka, A; Prchal-Murphy, M; Bednarik, K; Meissl, K; Putz, EM; Gotthardt, D; Sexl, V; Strobl, B; Müller, M (2015): Non-canonical TYK2 governs NK cell-mediated tumour surveillance. 3rd Annual Meeting of the International-Cytokine-and-Interferon-Society (ICIS), Bamberg, GERMANY, OCT 11-14, 2015. Cytokine (76), 1 79-79.

Publizierter (zitierfähiger) Beitrag für wissenschaftliche Veranstaltung in Proceedings (A2)

Bellutti, F; Prchal-Murphy, M; Rodriguez-Diez, E; Quereda, V; Malumbres, M; Sexl, V (2015): CDK4 and CDK6 cooperate in counteracting the INK4 family inhibitors during murine leukemogenesis. 75--EMBO EMBL Symposium: Frontiers in Stem Cells and Cancer; MAR 29-31, 2015; Heidelberg, GERMANY.

Doma, E; Grundschober, E; Hölbl-Kovacic, A; Sexl, V (2015): The role JAK2 in haematoploetic stem cells (HSCs). 98--EMBO EMBL Symposium: Frontiers in Stem Cells and Cancer; MAR 29-31, 2015; Heidelberg, GERMANY.

Edlinger, L; Prchal-Murphy, M; Gotthardt, D; Tigan, AS; Sexl, V (2015): The role of STAT5A and STAT5B in natural killer cells. -7th ÖGMBT Annual Meeting; SEP 9-11, 2015; Salzburg, AUSTRIA.

Edlinger, L; Putz, EM; Prchal-Murphy, M; Gotthardt, D; Tigan, AS; Hoelbl-Kovacic, A; Sexl, V (2015): The role of STAT5A and STAT5B in NK cells. -ÖGAI-Symposium 2015: 50 Years of B-Lymphocytes; DEC 11-12, 2015; Vienna, AUSTRIA.

Gotthardt, D; Putz, EM; Stockmann, C; Sexl, V (2015): STAT5 - the molecular switch from tumor surveillance to tumor promotion. -15th Meeting of the Society for Natural Immunity; MAY 2-6, 2015; Montebello, QUÉBEC, CANADA.

Grundschober, E; Hölbl-Kovacic, A; Sexl, V (2015): Deletion of Jak2 accelerates BCR-ABL induced leukaemia. -EMBO / EMBL Symposium: Frontiers in Stem Cells and Cancer; MAR 29-31, 2015; Heidelberg, GERMANY.

Menzl, I; Berger, A; Zuber, J; Eisinger-Fux, D; Sexl, V (2015): Linking cell cycle to transcription: CDKs in BCR-ABL driven leukemia. 114--Signal Transduction Society: 19th Joint Meeting "Signal Transduction - Receptors, Mediators and Genes"; NOV 2-4, 2015; Weimar, GERMANY.

Prchal-Murphy, M; Bellutti, F; Rodríguez-Díez, E; Quereda, V; Malumbres, M; Sexl, V (2015): INK4-mediated CDK6 activity controls hematopoietic progenitor potential. 177--EMBO / EMBL Symposium: Frontiers in Stem Cells and Cancer; MAR 29-31, 2015; Heidelberg, GERMANY.

Streicher, C; Heyny, A; Andrukhova, O; Schüler, C; Kollmann, K; Kantner, I; Sexl, V; Kleiter, M; Hofbauer, LC; Kostenuik, PJ; Erben, RG (2015): Estrogen Regulates Bone Turnover by Targeting RANKL Expression in Bone Lining Cells. -International Conference on Progress in Bone and Mineral Research 2015; DEC 03-05, 2015; Vienna, Austria.

Tigan, A; Uras, I; Prchal-Murphy, M; Bago-Horvath, Z; Kudweis, P; Scheicher, R; Kollmann, K; Sexl, V (2015): Loss of CDK6 accelerates JUNB driven myeloproliferative disease and leukemia. -HEMID 2015 Meeting "Epigenetic regulation of hematopoiesis and leukemogenesis"; APR 21-22, 2015; Strassburg, FRANCE.

Uras, I; Walter, G; Bellutti, F; Prchal-Murphy, M; Scheicher, R; Tigan, A; Valent, P; Scholl, C; Fröhling, S; Sexl, V (2015): CDK6: a novel transciptional angel on the treatment of an agressive subtype of AML. -ESH International Conference on Cute Myeloid Leukemia "Molecular and Translational": Advances in Biology and Treatment; SEP 10-12, 2015; Budapest, HUNGARY.

Originalbeitrag in Sammelwerk

** Schneckenleithner, C; Hoelbl-Kovacic, A; Sexl, V (2015): Modeling BCR/ABL-driven malignancies in the mouse. Methods Mol Biol. 2015; 1267:263-282

2014

Zeitschriftenaufsatz

** Berger, A; Hoelbl-Kovacic, A; Bourgeais, J; Hoefling, L; Warsch, W; Grundschober, E; Uras, IZ; Menzl, I; Putz, EM; Hoermann, G; Schuster, C; Fajmann, S; Leitner, E; Kubicek, S; Moriggl, R [and 2 others] (2014): PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis. Leukemia. 2014; 28(3):629-641
Open Access Logo

** Berger, A; Sexl, V; Valent, P; Moriggl, R (2014): Inhibition of STAT5: a therapeutic option in BCR-ABL1-driven leukemia. Oncotarget. 2014; 5(20):9564-9576
Open Access Logo

** Gotthardt, D; Prchal-Murphy, M; Seillet, C; Glasner, A; Mandelboim, O; Carotta, S; Sexl, V; Putz, EM (2014): NK cell development in bone marrow and liver: site matters. Genes Immun. 2014; 15(8):584-587

** Gotthardt, D; Putz, EM; Straka, E; Kudweis, P; Biaggio, M; Poli, V; Strobl, B; Müller, M; Sexl, V (2014): Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance. Blood. 2014; 124(15):2370-2379

** Grundschober, E; Hoelbl-Kovacic, A; Bhagwat, N; Kovacic, B; Scheicher, R; Eckelhart, E; Kollmann, K; Keller, M; Grebien, F; Wagner, KU; Levine, RL; Sexl, V (2014): Acceleration of Bcr-Abl+ leukemia induced by deletion of JAK2. Leukemia. 2014; 28(9):1918-1922
Open Access Logo

** Hoermann, G; Blatt, K; Greiner, G; Putz, EM; Berger, A; Herrmann, H; Cerny-Reiterer, S; Gleixner, KV; Walz, C; Hoetzenecker, K; Müllauer, L; Reiter, A; Sotlar, K; Sexl, V; Valent, P; Mayerhofer, M (2014): CD52 is a molecular target in advanced systemic mastocytosis. FASEB J. 2014; 28(8):3540-3551

** Klose, CS; Flach, M; Möhle, L; Rogell, L; Hoyler, T; Ebert, K; Fabiunke, C; Pfeifer, D; Sexl, V; Fonseca-Pereira, D; Domingues, RG; Veiga-Fernandes, H; Arnold, SJ; Busslinger, M; Dunay, IR [and 2 others] (2014): Differentiation of type 1 ILCs from a common progenitor to all helper-like innate lymphoid cell lineages. Cell. 2014; 157(2):340-356

** Kovacic, B; Hoelbl-Kovacic, A; Fischhuber, KM; Leitner, NR; Gotthardt, D; Casanova, E; Sexl, V; Müller, M (2014): Lactotransferrin-Cre reporter mice trace neutrophils, monocytes/macrophages and distinct subtypes of dendritic cells. Haematologica. 2014; 99(6):1006-1015
Open Access Logo

** Putz, EM; Gotthardt, D; Sexl, V (2014): STAT1-S727 - the license to kill. Oncoimmunology. 2014; 3(9):e955441
Open Access Logo

** Putz, EM; Hoelzl, MA; Baeck, J; Bago-Horvath, Z; Schuster, C; Reichholf, B; Kern, D; Aberger, F; Sexl, V; Hoelbl-Kovacic, A (2014): Loss of STAT3 in Lymphoma Relaxes NK Cell-Mediated Tumor Surveillance. Cancers (Basel). 2014; 6(1):193-210
Open Access Logo

** Rodríguez-Díez, E; Quereda, V; Bellutti, F; Prchal-Murphy, M; Partida, D; Eguren, M; Kollmann, K; Gómez de Cedrón, M; Dubus, P; Cañamero, M; Martínez, D; Sexl, V; Malumbres, M (2014): Cdk4 and Cdk6 cooperate in counteracting the INK4 family of inhibitors during murine leukemogenesis. Blood. 2014; 124(15):2380-2390

Kongressbeitrag in einer Zeitschrift

** Grundschober, E; Hoelbl-Kovacic, A; Bhagwat, N; Levine, R; Sexl, V (2014): Acceleration Of Bcr-Abl Plus Leukemia Induced By Deletion Of JAK2. 19th Congress of the European-Hematology-Association, Milan, ITALY, JUN 12-15, 2014. Haematologica (99), S1 794-794.

** Tarrio, M; Kallal, L; Sexl, V; Biron, C (2014): Signaling and function of STAT3 in NK cells during murine cytomegalovirus infection. Immunology 2014, Pittsburgh, Pa., United States (USA), MAY 2-6, 2014. J Immunol (192), S1 124.8.

Publizierter (zitierfähiger) Beitrag für wissenschaftliche Veranstaltung in Proceedings (A2)

Berger, A; Hoelbl-Kovacic, A; Menzl, I; Kubicek, S; Moriggl, R; Gouilleux, F; Sexl, V (2014): Characterization of STAT5 serine phosphorylation as a drug target in BCR-ABL+ leukemia. -24. Vetpharm Symposium; SEP 11-12,2014; Zuerich, SWITZERLAND.

Edlinger, L; Grundschober, E; Gotthardt, D; Putz, EM; Hoelbl-Kovacic, A; Sexl, V (2014): The role of STAT5A and STAT5B in leukemia and NK cell-mediated tumor surveillance. -Cell Death, Inflammation & Immunity; NOV 30 - DEC 3, 2014; Obergurgl, AUSTRIA.

Gotthardt, D; Putz, EM; Kudweis, P; Strobl, B; Sexl, V (2014): Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance. -Natural Killer Cell Symposium 2014; SEPT 10-12, 2014; Hannover, GERMANY.

Gotthardt, D; Putz, EM; Straka, E; Kudweis, P; Strobl,B; Mathias, M; Sexl, V (2014): Loss of STAT3 in Natural Killer Cells enhances NK cell dependent tumor surveillance. -10th YSA-PhD-Symposium 2014; JUN, 2014; Vienna, AUSTRIA.

Meissl, K; Klein, K; Witalisz, A; Prchal-Murphy, M; Sexl, V; Müller, M; Strobl, B (2014): STAT1 isoform specific functions in NK cell maturation and cytotoxicity. -Natural Killer Cell Symposium ; Sept 10-14, 2014; Hannover, Germany.

Putz, EM; Leitner, NR; Müller, M; Sexl, V (2014): A novel non-canonical role of STAT1 in NK cells. -6th ÖGMBT Annual Meeting ; Sept 15-18, 2014; Vienna, Austria.

Putz, EM; Leitner, NR; Müller, M; Sexl, V (2014): A novel non-canonical role of STAT1 in NK cells. -Natural Killer Cell Symposium; SEP 10-12, 2014; Hannover, GERMANY.

Sadovnik, I; Herrmann, H; Hoelbl, A; Cerny-Reiterer, S; Warsch, W; Blatt, K; Peter, B; Hoermann, G; Eisenwort, G; Bilban, M; Sill, H; Sperr, WR; Streubel, B; Willmann, M; Rülicke, T [and 4 others] (2014): Identification of CD25 (IL-2RA) and CD26 (DPPIV) as novel markers and potential targets on CD34+/CD38- LSC in Ph+ CML. -16th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy; SEP 4-7, 2014; Philadelphia, USA.

Sexl, V (2014): CDK6 - News and views. -6th International Conference on MPN; OCT 23-26, 2014; Estoril, PORTUGAL.

Sexl, V; Putz, EM; Gotthardt, D; Strobl, B; Decker, T; Müller, M (2014): STATs in the spotlight of NK cell mediated immune surveillance. -6th ÖGMBT Annual Meeting ; Sept 15-18, 2014; Vienna, Austria.

Witalisz, A; Prchal-Murphy, M; Bednarik, K; Meissl, K; Sexl, V; Strobl, B; Müller, M (2014): Kinase-inactive Tyk2 mediates NK cell-dependent tumour surveillance and CD8+ T cell crosstalk to NK cells. -Natural Killer Cell Symposium; Sept 10-14, 2014; Hannover, Germany.

2013

Zeitschriftenaufsatz

** Hannesdóttir, L; Tymoszuk, P; Parajuli, N; Wasmer, MH; Philipp, S; Daschil, N; Datta, S; Koller, JB; Tripp, CH; Stoitzner, P; Müller-Holzner, E; Wiegers, GJ; Sexl, V; Villunger, A; Doppler, W (2013): Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response. Eur J Immunol. 2013; 43(10):2718-2729

** Huang, J; Das, SK; Jha, P; Al Zoughbi, W; Schauer, S; Claudel, T; Sexl, V; Vesely, P; Birner-Gruenberger, R; Kratky, D; Trauner, M; Hoefler, G (2013): The PPARα agonist fenofibrate suppresses B-cell lymphoma in mice by modulating lipid metabolism. Biochim Biophys Acta. 2013; 1831(10):1555-1565
Open Access Logo

** Kantner, HP; Warsch, W; Delogu, A; Bauer, E; Esterbauer, H; Casanova, E; Sexl, V; Stoiber, D (2013): ETV6/RUNX1 induces reactive oxygen species and drives the accumulation of DNA damage in B cells. Neoplasia. 2013; 15(11):1292-1300
Open Access Logo

** Kollmann, K; Heller, G; Schneckenleithner, C; Warsch, W; Scheicher, R; Ott, RG; Schäfer, M; Fajmann, S; Schlederer, M; Schiefer, AI; Reichart, U; Mayerhofer, M; Hoeller, C; Zöchbauer-Müller, S; Kerjaschki, D [and 9 others] (2013): A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell. 2013; 24(2):167-181
Open Access Logo

** Kollmann, K; Sexl, V (2013): CDK6 and p16INK4A in lymphoid malignancies. Oncotarget. 2013; 4(11):1858-1859 Open Access Logo

** Köprülü, AD; Kastner, R; Wienerroither, S; Lassnig, C; Putz, EM; Majer, O; Reutterer, B; Sexl, V; Kuchler, K; Müller, M; Decker, T; Ellmeier, W (2013): The tyrosine kinase Btk regulates the macrophage response to Listeria monocytogenes infection. PLoS One. 2013; 8(3):e60476
Open Access Logo

** Koromilas, AE; Sexl, V (2013): The tumor suppressor function of STAT1 in breast cancer. JAKSTAT. 2013; 2(2):e23353
Open Access Logo

** Prchal-Murphy, M; Putz, EM; Freissmuth, M; Sexl, V; Zebedin-Brandl, E (2013): Targeting PI3Kδ: One man"s meat is another man"s poison. Oncoimmunology. 2013; 2(1):e22272
Open Access Logo

** Putz, EM; Gotthardt, D; Hoermann, G; Csiszar, A; Wirth, S; Berger, A; Straka, E; Rigler, D; Wallner, B; Jamieson, AM; Pickl, WF; Zebedin-Brandl, EM; Müller, M; Decker, T; Sexl, V (2013): CDK8-mediated STAT1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance. Cell Rep. 2013; 4(3):437-444
Open Access Logo

** Richter, K; Perriard, G; Behrendt, R; Schwendener, RA; Sexl, V; Dunn, R; Kamanaka, M; Flavell, RA; Roers, A; Oxenius, A (2013): Macrophage and T cell produced IL-10 promotes viral chronicity. PLoS Pathog. 2013; 9(11):e1003735
Open Access Logo

** Sullivan, RP; Fogel, LA; Leong, JW; Schneider, SE; Wong, R; Romee, R; Thai, TH; Sexl, V; Matkovich, SJ; Dorn, GW; French, AR; Fehniger, TA (2013): MicroRNA-155 tunes both the threshold and extent of NK cell activation via targeting of multiple signaling pathways. J Immunol. 2013; 191(12):5904-5913

** Warsch, W; Grundschober, E; Sexl, V (2013): Adding a new facet to STAT5 in CML: multitasking for leukemic cells. Cell Cycle. 2013; 12(12):1813-1814
Open Access Logo

** Warsch, W; Walz, C; Sexl, V (2013): JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia. Blood. 2013; 122(13):2167-2175

Kongressbeitrag in einer Zeitschrift

** Morvan, M; Champsaur, M; Johnson, N; Sexl, V; Lanier, L (2013): Novel mouse models reveal how expression of NKG2D and its ligands on various cell subsets affects immune responses. 100th Annual Meeting of the American-Association-of-Immunologists, Honolulu, USA, MAY 03-07, 2013. J Immunol (190) 183.11-183.11.

** Sadovnik, I; Herrmann, H; Cerny-Reiterer, S; Warsch, W; Blatt, K; Hoebl, A; Peter, B; Stefanzl, G; Hoermann, G; Herndlhofer, S; Streubel, B; Sperr, WR; Mannhalter, C; Sexl, V; Valent, P (2013): Evaluation of the IL-2R alpha chain (CD25) as novel marker of leukemic stem cells in Ph plus CML. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Vienna, AUSTRIA, OKT 18-22, 2013. Onkologie (36), S7 287-287.

** Sadovnik, I; Herrmann, H; Cerny-Reiterer, S; Warsch, W; Hoelbl, A; Blatt, K; Stefanzl, G; Hoermann, G; Herndlhofer, S; Streubel, B; Sperr, WR; Mannhalter, C; Sexl, V; Valent, P (2013): Neoplastic Stem Cells Of Ph Plus Chronic Myeloid Leukemia (Cml) Express The Alpha-Chain Of The Il-2 Receptor (Cd25). 18th Congress of the European Hematology Association, Stockholm, Sweden, June 13–16, 2013. Haematologica (98), S1 256-256.

Publizierter (zitierfähiger) Beitrag für wissenschaftliche Veranstaltung in Proceedings (A2)

Gotthardt, D; Putz, EM; Kudweis, P; Strobl, B; Sexl, V (2013): The Role of Stat3 in murine Natural Killer cells. -17th International Summer School on Immunology (FEBS); SEPT, 14-21; Rabac, CROATIA.

Kollmann, K; Heller, G; Schneckenleithner, C; Warsch, W; Scheicher, R; Ott, R; Schäfer, M; Fajmann, S; Schlederer, M; Schiefer, AI; Reichart, U; Mayerhofer, M; Hoeller, C; Zoechbauer-Mueller, S; Kerjaschki, D [and 9 others] (2013): A new kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. -FASEB Science Research Conferences: Hematologic Malignancies; AUG 4-9, 2013; Vermont, USA.

Sexl, V (2013): The breast cancer Immune stromal interface. -IMPAKT 2013 Breast Cancer Conference; MAY 2-5, 2013; Brussels, BELGIUM.

Sexl, V; Berger, A; Warsch, W; Grundschober, E; Höfling, L; Moriggl, R; Hölbl-Kovacic, A (2013): Stat5 - a central player in Bcr/Abl+ leukemia. -2nd FEBS Meeting on JAK-STAT Signalling: Model Organisms and Beyond at the Albert Hall Nottingham; SEP 12-15, 2013; Nottingham, United Kingdom.

Sexl, V; Berger, A; Warsch, W; Grundschober, E; Höfling, L; Moriggl, R; Hölbl-Kovacic, A (2013): Stat5 - a central player in Bcr/Abl+ leukemia. -42nd Annual Scientific Meeting, ISEH; AUG 22-25, 2013; Vienna, AUSTRIA.

2012

Zeitschriftenaufsatz

** Hantschel, O; Warsch, W; Eckelhart, E; Kaupe, I; Grebien, F; Wagner, KU; Superti-Furga, G; Sexl, V (2012): BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. Nat Chem Biol. 2012; 8(3):285-293

** Hassler, MR; Klisaroska, A; Kollmann, K; Steiner, I; Bilban, M; Schiefer, AI; Sexl, V; Egger, G (2012): Antineoplastic activity of the DNA methyltransferase inhibitor 5-aza-2"-deoxycytidine in anaplastic large cell lymphoma. Biochimie. 2012; 94(11):2297-2307
Open Access Logo

** Kernbauer, E; Maier, V; Stoiber, D; Strobl, B; Schneckenleithner, C; Sexl, V; Reichart, U; Reizis, B; Kalinke, U; Jamieson, A; Müller, M; Decker, T (2012): Conditional Stat1 ablation reveals the importance of interferon signaling for immunity to Listeria monocytogenes infection. PLoS Pathog. 2012; 8(6):e1002763
Open Access Logo

** Kovacic, B; Hoelbl, A; Litos, G; Alacakaptan, M; Schuster, C; Fischhuber, KM; Kerenyi, MA; Stengl, G; Moriggl, R; Sexl, V; Beug, H (2012): Diverging fates of cells of origin in acute and chronic leukaemia. EMBO Mol Med. 2012; 4(4):283-297
Open Access Logo

** Laimer, D; Dolznig, H; Kollmann, K; Vesely, PW; Schlederer, M; Merkel, O; Schiefer, AI; Hassler, MR; Heider, S; Amenitsch, L; Thallinger, C; Staber, PB; Simonitsch-Klupp, I; Artaker, M; Lagger, S [and 23 others] (2012): PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Nat Med. 2012; 18(11):1699-1704

** Mizutani, T; Neugebauer, N; Putz, EM; Moritz, N; Simma, O; Zebedin-Brandl, E; Gotthardt, D; Warsch, W; Eckelhart, E; Kantner, HP; Kalinke, U; Lienenklaus, S; Weiss, S; Strobl, B; Müller, M [and 2 others] (2012): Conditional IFNAR1 ablation reveals distinct requirements of Type I IFN signaling for NK cell maturation and tumor surveillance. Oncoimmunology. 2012; 1(7):1027-1037
Open Access Logo

** Putz, EM; Prchal-Murphy, M; Simma, OA; Forster, F; Koenig, X; Stockinger, H; Piekorz, RP; Freissmuth, M; Müller, M; Sexl, V; Zebedin-Brandl, E (2012): PI3Kδ is essential for tumor clearance mediated by cytotoxic T lymphocytes. PLoS One. 2012; 7(7):e40852
Open Access Logo

** Putz, EM; Schuster, C; Sexl, V (2012): Bcl-2: Live and let die. Oncoimmunology. 2012; 1(5):749-750
Open Access Logo

** Warsch, W; Grundschober, E; Berger, A; Gille, L; Cerny-Reiterer, S; Tigan, AS; Hoelbl-Kovacic, A; Valent, P; Moriggl, R; Sexl, V (2012): STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia. Oncotarget (3), 12 1669-1687.
Open Access Logo

Kongressbeitrag in einer Zeitschrift

** Schiefer, AI; Melcher, M; Bago-Horvath, Z; Eder, S; Skrabs, C; Hauswirth, A; Streubel, B; Mannhalter, C; Stoiber, D; Sexl, V; Mullauer, L; Jaeger, U; Porpaczy, EA (2012): A New Prognostic Score for Aggressive B-Cell Lymphoma with C-MYC Translocation Integrating Clinical and Genetic Features. 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta, USA, DEC 08-11, 2012. Blood (120), 21

Publizierter (zitierfähiger) Beitrag für wissenschaftliche Veranstaltung in Proceedings (A2)

Gotthardt, D; Putz, EM; Sexl, V (2012): STATs in the Spotlight of NKCell. -European Congress of Immunology; SEPT 6-8, 2012; Glasgow, SCOTLAND. Open Access Logo

Gotthardt D., Putz E.M., Sexl V (2012): STATs in the spotlight. -NK Cell Meeting; SEP 26 - 28, 2012; Heidelberg, Germany.

Warsch, W; Grundschober, E; Gille, L; Cerny-Reiterer, S; Valent, P; Sexl, V (2012): STAT5 triggers BCR-ABL mutations by mediating ROS Production. -ESH International Conference on Myeloprobliferative Neoplasms; OKT 4 - 6, 2012; Vienna, Austria.

Originalbeitrag in Sammelwerk

** Putz, EM; Zebedin, E; Sexl, V (2012): STAT Transcription Factors: Controlling All Aspects of NK Cell Biology. IN: Decker, T; Müller, M [Hrsg.]: JAK-Stat signaling: from basics to disease. Wien, Springer, pp. 187-204. ISBN: 978-3-7091-0890-1.

2011

Zeitschriftenaufsatz

** Eckelhart, E; Warsch, W; Zebedin, E; Simma, O; Stoiber, D; Kolbe, T; Rülicke, T; Mueller, M; Casanova, E; Sexl, V (2011): A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival and development. Blood. 2011; 117(5):1565-1573
Open Access Logo

** Friedbichler, K; Hoelbl, A; Li, G; Bunting, KD; Sexl, V; Gouilleux, F; Moriggl, R (2011): Serine phosphorylation of the Stat5a C-terminus is a driving force for transformation. Front Biosci (Landmark Ed). 2011; 16:3043-3056

** Kerjaschki, D; Bago-Horvath, Z; Rudas, M; Sexl, V; Schneckenleithner, C; Wolbank, S; Bartel, G; Krieger, S; Kalt, R; Hantusch, B; Keller, T; Nagy-Bojarszky, K; Huttary, N; Raab, I; Lackner, K [and 23 others] (2011): Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse. J Clin Invest. 2011; 121(5):2000-2012
Open Access Logo

** Kollmann, K; Heller, G; Ott, RG; Scheicher, R; Zebedin-Brandl, E; Schneckenleithner, C; Simma, O; Warsch, W; Eckelhart, E; Hoelbl, A; Bilban, M; Zöchbauer-Müller, S; Malumbres, M; Sexl, V (2011): c-JUN promotes BCR-ABL-induced lymphoid leukemia by inhibiting methylation of the 5" region of Cdk6. Blood. 2011; 117(15):4065-4075
Open Access Logo

** Kollmann, K; Heller, G; Sexl, V (2011): c-JUN prevents methylation of p16(INK4a) (and Cdk6): the villain turned bodyguard. Oncotarget. 2011; 2(5):422-427
Open Access Logo

** Kornfeld, JW; Isaacs, A; Vitart, V; Pospisilik, JA; Meitinger, T; Gyllensten, U; Wilson, JF; Rudan, I; Campbell, H; Penninger, JM; Sexl, V; Moriggl, R; van Duijn, C; Pramstaller, PP; Hicks, AA (2011): Variants in STAT5B associate with serum TC and LDL-C levels. J Clin Endocrinol Metab. 2011; 96(9):E1496-E1501
Open Access Logo

** Mueller, KM; Kornfeld, JW; Friedbichler, K; Blaas, L; Egger, G; Esterbauer, H; Hasselblatt, P; Schlederer, M; Haindl, S; Wagner, KU; Engblom, D; Haemmerle, G; Kratky, D; Sexl, V; Kenner, L [and 8 others] (2011): Impairment of hepatic growth hormone and glucocorticoid receptor signaling causes steatosis and hepatocellular carcinoma in mice. Hepatology. 2011; 54(4):1398-1409
Open Access Logo

** Schneckenleithner, C; Bago-Horvath, Z; Dolznig, H; Neugebauer, N; Kollmann, K; Kolbe, T; Decker, T; Kerjaschki, D; Wagner, KU; Müller, M; Stoiber, D; Sexl, V (2011): Putting the brakes on mammary tumorigenesis: loss of STAT1 predisposes to intraepithelial neoplasias. Oncotarget (2), 12 1043-1054.
Open Access Logo

** Schuster, C; Berger, A; Hoelzl, MA; Putz, EM; Frenzel, A; Simma, O; Moritz, N; Hoelbl, A; Kovacic, B; Freissmuth, M; Müller, M; Villunger, A; Müllauer, L; Schmatz, AI; Streubel, B [and 4 others] (2011): The cooperating mutation or "second hit" determines the immunologic visibility toward MYC-induced murine lymphomas. Blood. 2011; 118(17):4635-4645
Open Access Logo

** Strobl, B; Stoiber, D; Sexl, V; Mueller, M (2011): Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity. Front Biosci (Landmark Ed). 2011; 16:3214-3232

** Warsch, W; Kollmann, K; Eckelhart, E; Fajmann, S; Cerny-Reiterer, S; Hölbl, A; Gleixner, KV; Dworzak, M; Mayerhofer, M; Hoermann, G; Herrmann, H; Sillaber, C; Egger, G; Valent, P; Moriggl, R; Sexl, V (2011): High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood. 2011; 117(12):3409-3420
Open Access Logo

Kongressbeitrag in einer Zeitschrift

** Kenner, L; Laimer, D; Dolznig, H; Vesely, P; Kollmann, K; Schiefer, AII; Sexl, V; Staber, PB; Hoefler, G; Penninger, J; Inghirami, G; Ulrich, J (2011): New and Highly Efficient Therapy for Treatment NPM-ALK Associated Lymphomas. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, San Diego, CA, DEC 10-13, 2011. Blood (118), 21 721-721.

** Kernbauer, E; Jamieson, AM; Schneckenleithner, C; Sexl, V; Reichart, U; Strobl, B; Müller, M; Decker, T (2011): Conditional ablation of Stat1 reveals the antagonistic role of interferons in the clearance of the intracellular bacterial pathogen Listeria monocytogenes. 9th Joint Meeting of the International-Cytokine-Society/International-Society-for-Interferon-and-Cytokine-Research, Florence, ITALY, OCT 09-12, 2011. Cytokine (56), 1 10-11.

** Nivarthi, H; Tsyrulnyk, A; Warsch, W; Wang, ZQ; Winkler, S; Kenner, L; Müller, M; Baum, C; Bunting, KD; Sexl, V; Rülicke, T; Moriggl, R (2011): Generation of a Transgenic Mouse with Inducible Constitutively Active Stat5a. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, San Diego, CA, DEC 10-13, 2011. Blood (118), 21 1456-1456.

** Prchal, M; Kobolak, J; Teppner, I; Wallner, B; Semper, C; Lassing, C; Putz, EM; Dinnyes, A; Kolbe, T; Rulicke, T; Karaghiosoff, M; Sexl, V; Strobl, B; Müller, M (2011): Dissection of kinase-dependent and -independent functions of Tyk2 in immunity to infection and tumor-surveillance. 9th Joint Meeting of the International-Cytokine-Society/International-Society-for-Interferon-and-Cytokine-Research, Florence, ITALY, OCT 09-12, 2011. Cytokine (56), 1 86-86.

** Putz, EM; Zebedin-Brandl, EM; Decker, T; Prchal, M; Müller, M; Sexl, V (2011): STAT1 serine phosphorylation - Putting the brakes on NK cell activity. 9th Joint Meeting of the International-Cytokine-Society/International-Society-for-Interferon-and-Cytokine-Research, Florence, ITALY, OCT 09-12, 2011. Cytokine (56), 1 87-87.

Publizierter (zitierfähiger) Beitrag für wissenschaftliche Veranstaltung in Proceedings (A2)

Kernbauer, E; Jamieson, AM; Schneckenleithner, C; Sexl, V; Reichart, U; Strobl, B; Müller, M; Decker, T (2011): Conditional ablation of Stat1 reveals the antagonistic role of interferons in the clearance of the intracellular bacterial pathogen Listeria monocytogenes. -9th Joint Meeting of the ICS/ISICR; Okt 9-12, 2011; Florence, Italy.

Prchal, M; Kobolak, J; Teppner, I; Wallner, B; Semper, C; Lassnig, C; Putz, EM; Dinnyes, A; Kolbe, T; Rülicke, T; Karaghiosoff, M; Sexl, V; Strobl, B; Müller, M (2011): Dissection of kinase-dependent and -independent functions of Tyk2 in immunity to infection and tumor-surveillance. -9th Joint Meeting of the ICS/ISICR; OKT 9-12, 2011; Florence, Italy.

Putz, EM; Zebedin-Brandl, EM; Decke, T; Prchal, M; Müller, M; Sexl, V (2011): STAT1 serine phosphorylation - putting the brakes on NK cell activity. -9th Joint Meeting of the ICS/ISICR; OKT 9-12, 2011; Florence, Italy.

Sexl, V (2011): Cyclin dependent kinase 6 - a novel player in NPM-ALK driven lymphoma formation. -2nd Meeting of the European Research Initiative on ALCL; June 27-28,2011; Ludwig-Boltzmann Instiute for Cancer Research (LIBI-CR), Vienna, Austria.

2010

Zeitschriftenaufsatz

** Beer-Hammer, S; Zebedin, E; von Holleben, M; Alferink, J; Reis, B; Dresing, P; Degrandi, D; Scheu, S; Hirsch, E; Sexl, V; Pfeffer, K; Nürnberg, B; Piekorz, RP (2010): The catalytic PI3K isoforms p110gamma and p110delta contribute to B cell development and maintenance, transformation, and proliferation. J Leukoc Biol. 2010; 87(6):1083-1095
Open Access Logo

** El-Gazzar, A; Perco, P; Eckelhart, E; Anees, M; Sexl, V; Mayer, B; Liu, Y; Mikulits, W; Horvat, R; Pangerl, T; Zheng, D; Krainer, M (2010): Natural immunity enhances the activity of a DR5 agonistic antibody and carboplatin in the treatment of ovarian cancer. Mol Cancer Ther. 2010; 9(4):1007-1018
Open Access Logo

** Friedbichler, K; Kerenyi, MA; Kovacic, B; Li, G; Hoelbl, A; Yahiaoui, S; Sexl, V; Müllner, EW; Fajmann, S; Cerny-Reiterer, S; Valent, P; Beug, H; Gouilleux, F; Bunting, KD; Moriggl, R (2010): Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation. Blood. 2010; 116(9):1548-1558
Open Access Logo

** Hoelbl, A; Schuster, C; Kovacic, B; Zhu, B; Wickre, M; Hoelzl, MA; Fajmann, S; Grebien, F; Warsch, W; Stengl, G; Hennighausen, L; Poli, V; Beug, H; Moriggl, R; Sexl, V (2010): Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO Mol Med. 2010; 2(3):98-110
Open Access Logo

Kongressbeitrag in einer Zeitschrift

** Hantschel, OD; Eckelhart, E; Kaupe, I; Grebien, F; Wagner, KU; Sexl, V; Furga, GS (2010): Bcr Abl Directly Activates Stat5 Independent of Jak2. 52nd Annual Meeting of the American-Society-of-Hematology (ASH), Orlando, FL, DEC 04-07, 2010. Blood (116), 21 226-226.

Publizierter (zitierfähiger) Beitrag für wissenschaftliche Veranstaltung in Proceedings (A2)

Putz, EM; Zebedin-Brandl, EM; Prchal, M; Kovarik, P; Decker, T; Sexl, V (2010): Unexpected role of STAT1 serine727 for NK cell function. 4-4.-Annual Meeting of the Austrian Society for Allergology and Immunology (ÖGAI); DEC 3-5, 2010; Vienna, AUSTRIA.

2009

Zeitschriftenaufsatz

** Ecker, A; Simma, O; Hoelbl, A; Kenner, L; Beug, H; Moriggl, R; Sexl, V (2009): The dark and the bright side of Stat3: proto-oncogene and tumor-suppressor. Front Biosci (Landmark Ed). 2009; 14:2944-2958

** Pilz, A; Kratky, W; Stockinger, S; Simma, O; Kalinke, U; Lingnau, K; von Gabain, A; Stoiber, D; Sexl, V; Kolbe, T; Rülicke, T; Müller, M; Decker, T (2009): Dendritic cells require STAT-1 phosphorylated at its transactivating domain for the induction of peptide-specific CTL. J Immunol. 2009; 183(4):2286-2293
Open Access Logo

** Simma, O; Zebedin, E; Neugebauer, N; Schellack, C; Pilz, A; Chang-Rodriguez, S; Lingnau, K; Weisz, E; Putz, EM; Pickl, WF; Felzmann, T; Müller, M; Decker, T; Sexl, V; Stoiber, D (2009): Identification of an indispensable role for tyrosine kinase 2 in CTL-mediated tumor surveillance. Cancer Res. 2009; 69(1):203-211
Open Access Logo

2008

** Artwohl, M; Lindenmair, A; Sexl, V; Maier, C; Rainer, G; Freudenthaler, A; Huttary, N; Wolzt, M; Nowotny, P; Luger, A; Baumgartner-Parzer, SM (2008): Different mechanisms of saturated versus polyunsaturated FFA-induced apoptosis in human endothelial cells. J Lipid Res. 2008; 49(12):2627-2640
Open Access Logo

** Kornfeld, JW; Grebien, F; Kerenyi, MA; Friedbichler, K; Kovacic, B; Zankl, B; Hoelbl, A; Nivarti, H; Beug, H; Sexl, V; Muller, M; Kenner, L; Mullner, EW; Gouilleux, F; Moriggl, R (2008): The different functions of Stat5 and chromatin alteration through Stat5 proteins. Front Biosci. 2008; 13:6237-6254
Open Access Logo

** Mayerhofer, M; Gleixner, KV; Hoelbl, A; Florian, S; Hoermann, G; Aichberger, KJ; Bilban, M; Esterbauer, H; Krauth, MT; Sperr, WR; Longley, JB; Kralovics, R; Moriggl, R; Zappulla, J; Liblau, RS [and 4 others] (2008): Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens. J Immunol. 2008; 180(8):5466-5476
Open Access Logo

** Mayerhofer, M; Gleixner, KV; Mayerhofer, J; Hoermann, G; Jaeger, E; Aichberger, KJ; Ott, RG; Greish, K; Nakamura, H; Derdak, S; Samorapoompichit, P; Pickl, WF; Sexl, V; Esterbauer, H; Schwarzinger, I [and 3 others] (2008): Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib. Blood. 2008; 111(4):2200-2210
Open Access Logo

** Schuster, C; Müller, M; Freissmuth, M; Sexl, V; Stoiber, D (2008): Commentary on H. Ide et al., "Tyk2 expression and its signaling enhances the invasiveness of prostate cancer cells". Biochem Biophys Res Commun. 2008; 366(4):869-870

** Zebedin, E; Freissmuth, M; Sexl, V (2008): Signal interception-based therapies--a double-edged sword in Bcr/abl-induced malignancies? Conference on Targets and Targeted Drugs in Chronic Myeloid Leukemia, Vienna, AUSTRIA, OCT 26-28, 2007. Leuk Lymphoma. 2008; 49(4):620-624

** Zebedin, E; Simma, O; Schuster, C; Putz, EM; Fajmann, S; Warsch, W; Eckelhart, E; Stoiber, D; Weisz, E; Schmid, JA; Pickl, WF; Baumgartner, C; Valent, P; Piekorz, RP; Freissmuth, M; Sexl, V (2008): Leukemic challenge unmasks a requirement for PI3Kdelta in NK cell-mediated tumor surveillance. Blood. 2008; 112(12):4655-4664
Open Access Logo

2007

** Schuster, C; Fernbach, N; Rix, U; Superti-Furga, G; Holy, M; Freissmuth, M; Sitte, HH; Sexl, V (2007): Selective serotonin reuptake inhibitors--a new modality for the treatment of lymphoma/leukaemia? Biochem Pharmacol. 2007; 74(9):1424-1435

** Staber, PB; Vesely, P; Haq, N; Ott, RG; Funato, K; Bambach, I; Fuchs, C; Schauer, S; Linkesch, W; Hrzenjak, A; Dirks, WG; Sexl, V; Bergler, H; Kadin, ME; Sternberg, DW [and 2 others] (2007): The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling. Blood. 2007; 110(9):3374-3383
Open Access Logo

2006

** Hoelbl, A; Kovacic, B; Kerenyi, MA; Simma, O; Warsch, W; Cui, Y; Beug, H; Hennighausen, L; Moriggl, R; Sexl, V (2006): Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. Blood. 2006; 107(12):4898-4906
Open Access Logo

** Kovacic, B; Stoiber, D; Moriggl, R; Weisz, E; Ott, RG; Kreibich, R; Levy, DE; Beug, H; Freissmuth, M; Sexl, V (2006): STAT1 acts as a tumor promoter for leukemia development. Cancer Cell. 2006; 10(1):77-87
Open Access Logo

2005

** Hoeller, C; Pratscher, B; Thallinger, C; Winter, D; Fink, D; Kovacic, B; Sexl, V; Wacheck, V; Gleave, ME; Pehamberger, H; Jansen, B (2005): Clusterin regulates drug-resistance in melanoma cells. J Invest Dermatol. 2005; 124(6):1300-1307
Open Access Logo

** Moriggl, R; Sexl, V; Kenner, L; Duntsch, C; Stangl, K; Gingras, S; Hoffmeyer, A; Bauer, A; Piekorz, R; Wang, D; Bunting, KD; Wagner, EF; Sonneck, K; Valent, P; Ihle, JN; Beug, H (2005): Stat5 tetramer formation is associated with leukemogenesis. Cancer Cell (7), 1 87-99.

Kongressbeitrag in einer Zeitschrift

** Schuster, C; Schellack, C; Simma, O; Weisz, E; Muller, M; Sexl, V; Stoiber, D (2005): Loss of Tyk2 accelerates lymphoma formation in E mu-Myc transgenic mice. Pharmacology 2005; 75(4): 197-197.

2004

Zeitschriftenaufsatz

** Stoiber, D; Kovacic, B; Schuster, C; Schellack, C; Karaghiosoff, M; Kreibich, R; Weisz, E; Artwohl, M; Kleine, OC; Muller, M; Baumgartner-Parzer, S; Ghysdael, J; Freissmuth, M; Sexl, V (2004): TYK2 is a key regulator of the surveillance of B lymphoid tumors. J Clin Invest. 2004; 114(11):1650-1658
Open Access Logo

2003

** Sexl, V; Kovacic, B; Piekorz, R; Moriggl, R; Stoiber, D; Hoffmeyer, A; Liebminger, R; Kudlacek, O; Weisz, E; Rothammer, K; Ihle, JN (2003): Jak1 deficiency leads to enhanced Abelson-induced B-cell tumor formation. Blood. 2003; 101(12):4937-4943
Open Access Logo

1999

** Moriggl, R; Sexl, V; Piekorz, R; Topham, D; Ihle, JN (1999): Stat5 activation is uniquely associated with cytokine signaling in peripheral T cells. Immunity. 1999; 11(2): 225-230.

** Moriggl, R; Topham, DJ; Teglund, S; Sexl, V; McKay, C; Wang, D; Hoffmeyer, A; van Deursen, J; Sangster, MY; Bunting, KD; Grosveld, GC; Ihle, JN (1999): Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity (10), 2 249-259.

© Veterinärmedizinische Universität Wien Hilfe und Downloads